<p>Waldencast plc has sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. for $82.5 million. The sale is expected to strengthen Waldencast’s balance sheet as the company continues to explore strategic options. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840199-25-000078), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

WALD

<p>Waldencast plc has sold its "Obagi" trademark rights in Japan to Rohto Pharmaceutical Co., Ltd. for $82.5 million. This transaction aims to strengthen Waldencast's balance sheet as the company explores strategic options. The original content was published via EDGAR by Waldencast plc on November 14, 2025.</p>

Waldencast Sells Obagi Japan Trademark to Rohto for $82.5 Million